Castration-resistant metastatic prostate cancer and first-line treatments

Urology-nephrology

Prostate cancer is the most common cancer in men over 50. Currently, the overall survival of a patient with castration-resistant metastatic prostate cancer is estimated at 36 months.

Current first-line therapeutic approaches to this cancer include antiandrogens with abiraterone and chemotherapy with docetaxel and cabazitaxel.

The study by Duojie Zhang et al examined these first-line therapeutic strategies through a network meta-analysis. The main objective of this study was to assess the relative efficacy and safety of these therapeutic strategies.

Efficacy was compared in terms of overall survival and incidence of serious adverse events.

Results showed that docetaxel+prednisone and cabazitaxel+prednisone significantly improved overall survival, while abiraterone did not.

The combination of cabazitaxel + prednisone was recommended as the primary choice for first-line treatment of metastatic castration-resistant prostate cancer, due to its favorable safety profile and comparable efficacy at higher doses.

This study also highlighted the importance of considering the molecular and genetic characteristics of tumors to optimize patient outcomes.

Source(s) :
Zhang D, Weng H, Zhu Z, Gong W, Ma Y. Evaluating first-line therapeutic strategies for metastatic castration-resistant prostate cancer: a comprehensive network meta-analysis and systematic review. Front Oncol. 2024 Apr 15;14:1378993. doi: 10.3389/fonc.202 ;

COVID-19 and coagulation parameters: a link to mortality?

The COVID-19 pandemic, caused by SARS-CoV-2, has led to millions of deaths...

Resistance training and Multiple Sclerosis: a solution to improve function and quality of life?

Multiple sclerosis (MS) is a chronic autoimmune disease of the central ner...

Endometriosis: the Impact of hormones, sexual practice, and surgical treatments

Endometriosis is a chronic inflammatory disease modulated by estrogen leve...